The CS said there are enough supplies, specifically of TLD, pediatric ARVs, Nevirapine
suspension, and various HIV testing commodities.
She added that the supply of Nevirapine suspension, used for infant prophylaxis as part
of eliminating vertical transmission of HIV, remains stable.
Health Cabinet Secretary Deborah Mulongo with PS Mary Muthoni and KEMSA CEO Waqo Dulacha and other officials when she flagged off HIV-related supplies at MEDS in Nairobi on March 14, 2025/MOH
The government has reassured people living with HIV that its commitment to HIV response remains strong despite the prevailing foreign aid freeze by the US government.
Health Cabinet Secretary Deborah Mulongo affirmed that the country has sufficient stock of antiretroviral (ARV) drugs and HIV testing kits to ensure uninterrupted treatment and care.
Speaking when she flagged off a consignment of HIV-related medical supplies, Mulongo noted that there are enough supplies, specifically of TLD, pediatric ARVs, Nevirapine suspension, and various HIV testing commodities, which can last for close to two years.
"Our priority is, and always will be, to ensure that patients receive quality care, with adequate and readily available commodities," she said.
The supply chain supporting People Living with HIV, she said, is efficiently being coordinated by KEMSA, MEDS, MOH, and county governments.
Mulongo further stated that they are ensuring there is a consistent availability of Early Infant Diagnosis and Viral Load testing reagents.
She highlighted that there is the availability of 2,026,555 packs of TLD, the main ART regimen used by over 92 per cent of patients, translating to 4.7 months of stock.
According to Mulongo, additional packs of over 4.8 million are expected by June 2025, increasing central-level stocks to more than 11 months by midyear.
For pediatric patients, she confirmed that there are over 326,000 packs of Abacavir/Lamivudine (120/60mg) dispersible tablets, enough to last 7.4 months.
Plans are also underway to introduce a fixed-dose pediatric combination from August 2025, with 18 months of stock already on order, she said.
The supply of Nevirapine suspension, used for infant prophylaxis as part of eliminating vertical transmission of HIV, remains stable, with the CS disclosing that 510,000 bottles are currently available, covering 8.4 months of stock.
In addition to ARVs, Mulongo said the country has sufficient HIV testing kits, including 8.3 million Trinscreen tests, translating to 10 months of stock, and 1.48 million HIV/Syphilis duo tests, covering 14.5 months.
She said her ministry is expediting the delivery of over 52,000 Early Infant Diagnosis (EID) tests by April 2025 to support uninterrupted service delivery.
Viral load testing also remains a priority, with 446,436 tests available, translating to 3.5 months of stock, and additional supplies expected by April 2025.
Regarding male condoms, the CS said this has also been secured, with over 1.6 million pieces in stock and a recent distribution of 9 million pieces to health facilities.
To further strengthen HIV prevention efforts, she noted that the ministry is expediting the delivery of 28 million additional pieces, while another 93 million are under procurement at KEMSA.
Kenya, home to approximately 1.4 million people living with HIV, has made remarkable progress toward the UNAIDS 95-95-95 targets, achieving 98-98-94, signifying strong diagnosis, treatment coverage, and viral suppression rates.
The flagging off of the consignment from MEDS, operating as an agent of KEMSA, will ensure that all health facilities in the country are adequately stocked with key HIV health products, she said.
Present during the event were Public Health Principal Secretary Mary Mutho and top officials from KEMSA, including CEO Waqo Dulacha.
